[go: up one dir, main page]

MXPA05009359A - Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6. - Google Patents

Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.

Info

Publication number
MXPA05009359A
MXPA05009359A MXPA05009359A MXPA05009359A MXPA05009359A MX PA05009359 A MXPA05009359 A MX PA05009359A MX PA05009359 A MXPA05009359 A MX PA05009359A MX PA05009359 A MXPA05009359 A MX PA05009359A MX PA05009359 A MXPA05009359 A MX PA05009359A
Authority
MX
Mexico
Prior art keywords
modulators
substituted tetrahydroisoquinolines
formula
compounds
methods
Prior art date
Application number
MXPA05009359A
Other languages
English (en)
Inventor
George Putman David
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA05009359A publication Critical patent/MXPA05009359A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion proporciona compuestos de la formula: (ver formula I) y las sales o profarmacos farmaceuticamente aceptables de los mismos, en los que n, X, Y, R1, R2, R3, R4 y R5 son como se definen en la presente. La invencion proporciona ademas metodos para preparar composiciones que comprenden y metodos para usar compuestos de la formula I, como moduladores de 5-HT6 para el tratamiento de enfermedades del Sistema Nervioso Central.
MXPA05009359A 2003-03-03 2004-02-23 Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6. MXPA05009359A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45151603P 2003-03-03 2003-03-03
PCT/EP2004/001751 WO2004078176A1 (en) 2003-03-03 2004-02-23 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators

Publications (1)

Publication Number Publication Date
MXPA05009359A true MXPA05009359A (es) 2005-11-04

Family

ID=32962598

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009359A MXPA05009359A (es) 2003-03-03 2004-02-23 Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.

Country Status (18)

Country Link
US (1) US7196088B2 (es)
EP (1) EP1601358B1 (es)
JP (1) JP2006515341A (es)
KR (1) KR100751604B1 (es)
CN (1) CN100395237C (es)
AR (1) AR043436A1 (es)
AT (1) ATE381334T1 (es)
AU (1) AU2004216813B2 (es)
BR (1) BRPI0407976A (es)
CA (1) CA2517146A1 (es)
CL (1) CL2004000382A1 (es)
DE (1) DE602004010791T2 (es)
ES (1) ES2297386T3 (es)
MX (1) MXPA05009359A (es)
PL (1) PL378754A1 (es)
RU (1) RU2327689C2 (es)
TW (1) TW200426145A (es)
WO (1) WO2004078176A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007956A1 (en) * 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
DK1497266T3 (da) 2002-03-27 2008-10-06 Glaxo Group Ltd Quinolinderivater og deres anvendelse som 5HT6-ligander
ATE313532T1 (de) 2003-07-22 2006-01-15 Arena Pharm Inc Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
US20080051387A1 (en) * 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
BRPI0720862A2 (pt) * 2006-12-27 2014-02-25 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos como inibidores de rho-cinase
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
ES2359170T3 (es) 2007-07-19 2011-05-19 Laboratorios Del Dr. Esteve S.A. Compuestos tetrahidro-quinolín-sulfonamida sustituidos, su preparación y uso como medicamentos.
TW200927731A (en) 2007-09-14 2009-07-01 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
KR101520086B1 (ko) 2007-09-14 2015-05-14 얀센 파마슈티칼스 인코포레이티드 １´,３´-이치환된-４-페닐-３,４,５,６-테트라히드로-２ｈ,１´ｈ-[１,４´]비피리디닐-２´-온
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
RU2512283C2 (ru) 2008-11-28 2014-04-10 Янссен Фармасьютикалз, Инк. Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
KR101753826B1 (ko) 2009-05-12 2017-07-04 얀센 파마슈티칼즈, 인코포레이티드 1,２,４―트리아졸로［４,３―ａ］피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
AU2011328195B2 (en) 2010-11-08 2015-04-02 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
EP3307260A4 (en) 2015-06-12 2019-02-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES FOR PROPHYLAXIS AND TREATMENT OF SLEEP BEHAVIORAL DISORDERS IN THE REM PHASE
HUE043310T2 (hu) 2015-07-06 2019-08-28 Gilead Sciences Inc COT modulátorok és eljárások alkalmazásukra
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
EP4126231A1 (en) 2020-03-30 2023-02-08 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
US11845737B2 (en) 2020-04-02 2023-12-19 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586794T2 (de) 1984-12-21 1993-05-27 Duphar Int Res Arzneimittel mit psychotroper wirkung.
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
IL110172A (en) 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
AU7548298A (en) * 1997-05-30 1998-12-30 Meiji Seika Kaisha Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
US6316450B1 (en) * 1997-07-11 2001-11-13 Smithkline Beecham P.L.C. Compounds
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
BR0009650A (pt) * 1999-04-09 2002-01-02 Meiji Seika Kaisha Composto, composição farmacêutica, processos para inibir a secreção de uma lipoproteìna contendo apolipoproteìna b, para inibir a biossìntese de triglicerìdeos e para prevenir ou tratar hiperlipidemia, doenças arterioscleróticas e pancreatite, e, uso do composto
AU1542201A (en) * 1999-11-05 2001-05-14 Nps Allelix Corp. Compounds having 5-HT6 receptor antagonist activity
US7157463B2 (en) 2001-01-23 2007-01-02 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
WO2002102774A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物

Also Published As

Publication number Publication date
CN100395237C (zh) 2008-06-18
AU2004216813A1 (en) 2004-09-16
DE602004010791D1 (de) 2008-01-31
TW200426145A (en) 2004-12-01
DE602004010791T2 (de) 2008-12-04
CA2517146A1 (en) 2004-09-16
AR043436A1 (es) 2005-07-27
WO2004078176A1 (en) 2004-09-16
US7196088B2 (en) 2007-03-27
EP1601358A1 (en) 2005-12-07
RU2327689C2 (ru) 2008-06-27
PL378754A1 (pl) 2006-05-15
EP1601358B1 (en) 2007-12-19
CN1756550A (zh) 2006-04-05
KR20050106069A (ko) 2005-11-08
AU2004216813B2 (en) 2008-09-11
CL2004000382A1 (es) 2005-01-07
ES2297386T3 (es) 2008-05-01
ATE381334T1 (de) 2008-01-15
US20040180874A1 (en) 2004-09-16
KR100751604B1 (ko) 2007-08-22
JP2006515341A (ja) 2006-05-25
BRPI0407976A (pt) 2006-03-07
RU2005130514A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
MXPA04007470A (es) Piridinonas sustituidas.
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
RS20060129A (en) /1,8/naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200517109A (en) Substituted pyridinones
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
BG106586A (en) Pyrazolopyramidines as therapeutic agents
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
YU59602A (sh) Aril fuzionisana azapoliciklična jedinjenja
MY135841A (en) Novel benzodioxoles
JO2372B1 (en) Source drugs of 4-phenylpyridine derivatives
MXPA04005456A (es) Derivados de acetileno que tienen actividad antagonistica de mglur5.
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
MXPA05010621A (es) Pirimidinonas sustituidas.
TW200612936A (en) Indole derivatives
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
MY136824A (en) Substituted benzoxazinones and uses thereof
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
MY138826A (en) 2,7-substituted indoles

Legal Events

Date Code Title Description
FG Grant or registration